About GARDP

The Global Antibiotic Research & Development Partnership (GARDP) accelerates the development and access of treatments for drug-resistant bacterial infections. Together with public, private and non-profit partners, GARDP works to preserve the power of antibiotics for generations to come.

GARDP is acting now to counter antibiotic resistance and save lives

Antimicrobial resistance (including antibiotic resistance) is one of the top 10 global health threats. In 2019, nearly 1.3 million people died as a result of drug-resistant bacterial infections, nearly as many as HIV and malaria combined. If left unchecked, antibiotic resistance may kill as many as 10 million people each year from 2050.

Child Mother Parents Family

Centering antibiotic drug development on public health needs

Female Scientists Pipetting In A Laboratory
Integrating R&D and access

We integrate as early as possible the constraints of public health needs and access challenges into the selection of our projects, so that these projects eventually benefit patients globally. We are directly involved in pharmaceutical and clinical development to ensure that every treatment we develop is safe, effective, affordable and suitable for use in diverse settings, including those with high AMR burden and limited resources.

Asian Female Cancer Patient With Headscraf Look Happy Have A Hug
Collaboration and license agreements

We de-risk antibiotic drug development projects by negotiating collaboration and licensing agreements with pharmaceutical companies. In exchange for our expertise and financial support, we seek the rights to manufacture and distribute treatments, through sublicensees, in regions with high morbidity and mortality due antibiotic resistance.

Seamus Bangrak 3
Equal partnership

Many low- and middle-income countries have expertise that is critical to address the global antibiotic crisis. Our public-private partnership model involves working with these individuals and all key stakeholders from the get-go to coordinate efforts in the antibiotic pipeline of drug development and access.

Impact to date

Simphiwe Zwide - MSF Treatment For TB in South Africa.
Driving access to antibiotics for appropriate use

GARDP signed a first-of-its-kind license and technology transfer agreement with Shionogi and a collaboration agreement with Shionogi and CHAI that together aim to significantly transform the landscape of access to antibiotics for countries around the world.

African American female Doctor in the operating room putting drugs through an IV
Addressing serious bacterial infections

GARDP welcomed the FDA’s decision to accept for review the New Drug Application for cefepime-taniborbactam, developed by Venatorx Pharmaceuticals in partnership with GARDP. If approved, cefepime-taniborbactam will be the first antibiotic treatment to be launched in collaboration with GARDP.

3e1a0780
Advancing children’s antibiotics

GARDP with partners completed one of the largest ever observational studies on the care of babies with sepsis—3,200 newborns in 11 countries worldwide. GARDP has used data from the study to design “NeoSep1”, a trial to identify improved treatment regimens for newborns with sepsis. GARDP is also accelerating the paediatric development of novel antibiotics like cefepime-taniborbactam.

Mid Section Of Young Woman Wearing Denim Jacket Over Summer Dress With Floral Pattern
Addressing sexually transmitted infections

GARDP has successfully completed a global phase 3 trial of a new first-in-class antibiotic, zoliflodacin, to treat uncomplicated gonorrhoea. If approved by the US FDA, it will be the first new antibiotic for treating gonorrhoea in decades.

Close-up shot of microscope with metal lens at laboratory.
Advancing discovery and exploratory research

GARDP has screened over 130,000 compounds plus extracts of natural compounds for antibiotic activity against two WHO priority pathogens. GARDP is now testing and optimizing chemical series (each corresponding to a promising compound) for possible development.

Modern Medical Research Laboratory: Two Smiling Male Scientists / Doctors
Sharing cutting-edge antimicrobial research

GARDP’s REVIVE is leading efforts to preserve and freely share scientific knowledge and tools for antimicrobial R&D at the global level, notably with freely available webinars that feature experts in the field from around the world. 

Crowd Of People Walking Street Wearing Masks
Forging partnerships

GARDP partners with research and healthcare institutions around the world including those in regions that are heavily affected by drug resistance, drawing on local expertise and skills and building local capacity as needed.

GARDP envisions a world where all infections are treatable for everyone, everywhere.

Happy Indian Family Having Fun Outdoor Hindu Parents Laughing

Responding to a global health crisis: The story of GARDP

Responding to a global health crisis: The story of GARDP

GARDP was created in 2016 by WHO and the Drugs for Neglected Disease initiative (DNDi) to deliver on the 2015 Global Action Plan on Antimicrobial Resistance. Following an initial incubation period in DNDi, GARDP was legally established as the GARDP Foundation in Switzerland in 2018. 

Who Gardp Quote (1)

“The rise of drug-resistant bacteria is jeopardizing decades of progress and threatening our ability to prevent and treat infections that were once easy to treat. The Global Antibiotic Research and Development Partnership is an essential element of delivering the Global Action Plan on Antimicrobial Resistance.”

– Dr Tedros Adhanom Ghebreyesus, WHO Director-General